title: High incidence of high-risk HPV in benign and malignant lesions of the larynx.
abstract: The aim of this study was to determine the prevalence of human papillomavirus (HPV) in patients with laryngeal benign lesions (LBLs) and laryngeal squamous cell carcinomas (LSCCs) using a sensitive E6/E7 type-specific PCR. Paraffin-embedded samples from LBL (n=39) and LSCC patients (n=67) were evaluated for the presence of HPV DNA by GP5+/GP6+ consensus PCR and E6/E7 type-specific PCR for HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68. In LSCCs, immunohistochemical staining of p16, p53 and EGFR was also assessed. The E6/E7 type-specific PCR showed that 44 out of 59 LSCC patients (i.e., 75%) had high-risk (hr) HPV types and that 27 out of 35 LBL patients (i.e., 77%) had hrHPV types. HPV-16 viral load was significantly higher in LSCC than in LBL patients (p<10-6). The presence of hrHPV DNA did not correlate with the proportion of disease-free patients. Comparable levels of p16, p53 and EGFR expression were observed in the hrHPV+ tumor group (100% p16+, 56% p53+ and 97% EGFR+) and in the HPV- or low-risk (lr) HPV+ tumor group (92% p16+, 66% p53+ and 100% EGFR+). A very high prevalence of oncogenic HPV-16 was found in a series of benign and malignant laryngeal lesions. LSCC appears to be characterized by an active hrHPV infection. In LSCCs, the hrHPV+ subgroup had a similar prognosis (in terms of risk of recurrence) as the HPV- subgroup.
authors.affiliation: Laboratory of Anatomy, Faculty of Medicine and Pharmacy, University of Mons, Mons, Belgium.
authors.forename: Anaëlle
authors.initials: A
authors.lastname: Duray
authors.forename: Géraldine
authors.initials: G
authors.lastname: Descamps
authors.forename: Mohammad
authors.initials: M
authors.lastname: Arafa
authors.forename: Christine
authors.initials: C
authors.lastname: Decaestecker
authors.forename: Myriam
authors.initials: M
authors.lastname: Remmelink
authors.forename: Nicolas
authors.initials: N
authors.lastname: Sirtaine
authors.forename: Perle
authors.initials: P
authors.lastname: Ernoux-Neufcoeur
authors.forename: Eugène
authors.initials: E
authors.lastname: Mutijima
authors.forename: Joan
authors.initials: J
authors.lastname: Somja
authors.forename: Christophe E
authors.initials: CE
authors.lastname: Depuydt
authors.forename: Philippe
authors.initials: P
authors.lastname: Delvenne
authors.forename: Sven
authors.initials: S
authors.lastname: Saussez
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology* / Q000473:pathology / Q000821:virology; D002648:Child; D019941:Cyclin-Dependent Kinase Inhibitor p16; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D052162:Human papillomavirus 16 / Q000235:genetics / Q000502:physiology; D006801:Humans; D015994:Incidence; D007822:Laryngeal Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology* / Q000473:pathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism; D027383:Papillomaviridae / Q000235:genetics / Q000502:physiology*; D030361:Papillomavirus Infections / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology* / Q000821:virology; D011379:Prognosis; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D019562:Viral Load; D055815:Young Adult
chemical_list: C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D009363:Neoplasm Proteins; D016159:Tumor Suppressor Protein p53; D066246:ErbB Receptors